In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Asia Raises Bar for New Drugs, Manufacturers With Tougher CMC Reviews, GMP Inspections (Part 1)

This article was originally published in PharmAsia News

Executive Summary

As Asian drug regulatory authorities gain confidence in their ability to regulate new drug products, they are subjecting applicants to increasingly extensive chemistry, manufacturing and controls reviews, more like those of first-tier authorities in the U.S. and Europe

You may also be interested in...



Common Language For Regulatory Harmonization Takes Shape In Asia, But Mutual Recognition Unlikely Anytime Soon

Regulators, industry and health care agencies are increasingly using the same language to describe efforts at harmonization for drug approvals and manufacturing. But even though mutual recognition agreements on drug approvals are the “ultimate goal,” getting there in Asia could take a decade or more.

Japan Rolls Out GMP Revisions For PIC/S Compliance, But Integration Questions Linger

Japan’s PMDA moved swiftly to attach PIC/S guidance to existing guidelines. The agency is still working to integrate domestic GMP with international guidelines.

Asia Raises Bar for New Drugs, Manufacturers With Tougher CMC Reviews, GMP Inspections: A Look At India (Part 6)

Like most other Asian nations, India will not consider an application for marketing approval of a drug unless it comes with a certificate of pharmaceutical product showing that a major market has already approved the product, said Mark Rosolowsky, executive director, GRS-CMC, Bristol-Myers Squibb

Related Content

UsernamePublicRestriction

Register

SC073881

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel